Abstract
HIV protease plays a crucial role in the viral life cycle. It can cleave a series of heptamers in the viral Gag and GagPol precursor proteins to generate mature infectious virus particles. Successful inhibition of the protease will prevent this maturation step and hence block the spreading of HIV. However, the rapid emergence of drug resistance makes it urgent to develop new HIV protease inhibitors to combat the global disease. Besides, poor oral bioavailability, unacceptable side effects, high treatment cost and pill burden also trouble the application of HIV protease inhibitors. In such situations, non-peptidomimetic HIV protease inhibitors have drawn an increasing interest as a potential therapeutic option due to their small molecular weight, favorable bioavailability, high stability in vivo, low resistance and cost of production. In this review, we present the recent advances in non-peptidomimetic HIV protease inhibitors. Their design strategies, biological activities, resistance profiles, as well as clinical application will also be discussed.
Keywords: Antiviral, drug-resistance, human immunodeficiency virus, non-peptidomimetic inhibitors, protease inhibitors.
Current Medicinal Chemistry
Title:Advances in Non-peptidomimetic HIV Protease Inhibitors
Volume: 21 Issue: 17
Author(s): X. Pang, Z. Liu and G. Zhai
Affiliation:
Keywords: Antiviral, drug-resistance, human immunodeficiency virus, non-peptidomimetic inhibitors, protease inhibitors.
Abstract: HIV protease plays a crucial role in the viral life cycle. It can cleave a series of heptamers in the viral Gag and GagPol precursor proteins to generate mature infectious virus particles. Successful inhibition of the protease will prevent this maturation step and hence block the spreading of HIV. However, the rapid emergence of drug resistance makes it urgent to develop new HIV protease inhibitors to combat the global disease. Besides, poor oral bioavailability, unacceptable side effects, high treatment cost and pill burden also trouble the application of HIV protease inhibitors. In such situations, non-peptidomimetic HIV protease inhibitors have drawn an increasing interest as a potential therapeutic option due to their small molecular weight, favorable bioavailability, high stability in vivo, low resistance and cost of production. In this review, we present the recent advances in non-peptidomimetic HIV protease inhibitors. Their design strategies, biological activities, resistance profiles, as well as clinical application will also be discussed.
Export Options
About this article
Cite this article as:
Pang X., Liu Z. and Zhai G., Advances in Non-peptidomimetic HIV Protease Inhibitors, Current Medicinal Chemistry 2014; 21 (17) . https://dx.doi.org/10.2174/0929867321666140217115951
DOI https://dx.doi.org/10.2174/0929867321666140217115951 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Virtual Screening-Based Discovery of Potent Hypoglycemic Agents: In Silico, Chemical Synthesis and Biological Study
Current Computer-Aided Drug Design Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Current Vascular Pharmacology Fangchinoline, an Extract of the <i>Stephania tetrandra</i> S. Moore Root, Promoted Oxidative Stress-induced DNA Damage and Apoptosis and Inhibited Akt Signaling in Jurkat T Cells
Current Molecular Pharmacology The Superior Mesenteric Artery: From Syndrome in the Young to Vascular Atherosclerosis in the Old
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Hot Topic: Neuroprotection and Neuroregeneration in Ischemic Stroke: Emerging Treatment Strategies and Potential Molecular Targets)
Current Drug Targets Preface:
Current Vascular Pharmacology Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors
Current Topics in Medicinal Chemistry Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews The Digenea Parasite Opisthorchis felineus: A Target for the Discovery and Development of Novel Drugs
Infectious Disorders - Drug Targets Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies
Cardiovascular & Hematological Disorders-Drug Targets A Review on Deep Learning Architecture and Methods for MRI Brain Tumour Segmentation
Current Medical Imaging Transcription Factors as Molecular Targets: Molecular Mechanisms of Decoy ODN and their Design
Current Drug Targets Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator
Current Pharmaceutical Design The Significance of Endothelium-Derived Hyperpolarizing Factor in the Human Circulation
Current Vascular Pharmacology Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology NMDA/NR2B Selective Antagonists in the Treatment of Ischemic Brain Injury
Current Drug Targets - CNS & Neurological Disorders Tetraspanins-Structural and Signalling Scaffolds that Regulate Platelet Function
Mini-Reviews in Medicinal Chemistry Biobanks between Common Good and Private Interest: The Example of Umbilical Cord Blood Private Biobanks
Recent Patents on DNA & Gene Sequences